Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine

Journal of Psychopharmacology

Volumn 19, Issue 5 SUPPL., 2005, Pages 32-38

  Gastpar, M ^a   Masiak, M ^b   Latif, M A ^c   Frazzingaro, S ^d   Medori, R ^e   Lombertie, E R ^f  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c SUSSEX COMMUNITY NHS FOUNDATION TRUST   (United Kingdom)

^d DSM ASL 22   (Italy)

^e Janssen Cilag EMEA Belgium   (Belgium)

^f CENTRE HOSPITALIER ESQUIROL   (France)

Author keywords

Antipsychotics for injection; Efficacy; Long acting; Olanzapine; Risperidone

Indexed keywords

LONG ACTING DRUG; OLANZAPINE; RISPERIDONE;

ADULT; AKATHISIA; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; OPEN STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RATING SCALE; REMISSION; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; BODY WEIGHT; DELAYED-ACTION PREPARATIONS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUALITY OF LIFE; RISPERIDONE; TREATMENT OUTCOME;

EID: 25844487522     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881105056598     Document Type: Article

References (28)

1. Adams SGJ, Howe J T (1993) Predicting medication compliance in a psychotic population. J Nerv Ment Dis 181: 558-560
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4 edn. American Psychiatric Association
3. Berry S A, Clark A, Crumbley E, Zhu Y, Lasser R A (2004) Patients switched from olanzapine to long-acting risperidone in schizophrenia. 157th Annual Meeting of the American Psychiatric Association, New York, USA
4. Bhana N, Foster R H, Olney R, Plosker G L (2001) Olanzapine. An updated review of its use in the management of schizophrenia. Drugs 61: 111-161
5. Chouinard G, Ross-Chouinard A, Annable L (1980) The extrapyramidal symptom rating scale [abstract]. Can J Neurol Sci 7: 233
6. Chue P (2002) Switching - who, when and how? Int. J. Neuropsychopharmacol. 5 (Suppl 1): S223
7. Davis J M, Andriukaitis S (1986) The natural course of schizophrenia and effective maintenance drug treatment. J Clin Psychopharmacol 6 (Suppl 1): 2S-10S
8. Davis J M, Chen N (2003) Choice of maintenance medication for schizophrenia. J Clin Psychiatry 64 (Suppl 16): 24-33
9. Dolder C R, Lacro J P, Dunn L B, Jeste D V (2002) Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 159: 103-108
10. Fleischhacker W W, Eerdekens M, Karcher K, Remington G, Llorca P, Chrzanowski W, Martin S, Gefvert O (2003) Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 64: 1250-1257
11. Guy W (1976) Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare publication (ADM) 76-338. National Institute of Mental Health, Rockville, MD, pp. 218-222
12. Hogan T P, Awad A G, Eastwood R (1983) A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 177-183
13. Javitt D C (1999) Treatment of negative and cognitive symptoms. Curr Psychiatry Rep 1: 25-30
14. Kane J M, Eerdekens M, Lindenmayer J P, Keith S J, Lesem M, Karcher K (2003) Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160: 1125-1132
15. Kane J M, Lasser R, Bossie C, Zhu Y, Mahalchick L, Gharabawi G (2004) Long-Acting Risperidone: Exploring Remission in Schizophrenia. American Psychiatric Association, New York
16. Kay S R, Fiszbein A, Opler L A (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276
17. Keith S J, Kane J M (2003) Partial compliance and patient consequences in schizophrenia: our subjects can do better. J Clin Psychiatry 64: 1308-1315
18. Lasser R, Bossie C A, Gharabawi G, Eerdekens M, Nasrallah H A (2004a) Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J Affect Disord 83: 263-275
19. Lasser R A, Bossie C A, Gharabawi G M, Turner M (2004b) Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Euro Psychiatry 19: 219-225
20. Lauriello J, McEvoy J P, Rodriguez S, Bossie C A, Lasser R A (2005) Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophr Res 72: 249-258
21. Marder S R, Davis J M, Chouinard G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58: 538-546
22. Moller H J, Llorca P M, Sacchetti E, Martin S D, Medori R, Parellada E (2005) Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 20: 121-130
23. Möller H J, Gagiano C A, Addington D E, von Knorring L, Torres-Plank J F, Gaussares C (1998) Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. Int Clin Psychopharmacol 13: 99-106
24. Nasrallah H A, Duchesne I, Mehnert A, Janagap C, Eerdekens M (2004) Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry 65: 531-536
25. Purdon S E, Malla A, Labelle A, Lit W (2001) Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 26: 137-149
26. Stanniland C, Taylor D (2000) Tolerability of atypical antipsychotics. Drug Saf 22: 195-214
27. van Os J, Bossie C A, Lasser R (2004) Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol 19: 229-232
28. Ware J, Snow K, Kosinski M, Gandek B (1993) SF-36 Health Survey Manual and Interpretation Guide. The Health Institute, The Health Institute